Product Description
Digoxin is used to treat heart failure and abnormal heart rhythms (arrhythmias). It helps the heart work better and it helps control your heart rate. (Sourced from: https://medlineplus.gov/druginfo/meds/a682301.html)
Mechanisms of Action: ATPase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Germany, Sweden, United States
Active Clinical Trial Count: 31
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Breast Cancer|Chronic Obstructive Pulmonary Disease|General Diabetes|Healthy Volunteers|Influenza, Human|Non-Small-Cell Lung Cancer|Obesity|Overweight|Pain Unspecified|Prostate Cancer|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07269756 |
HRS-7535-110 | P1 |
Recruiting |
Obesity|Overweight |
2026-02-01 |
88% |
2026-01-01 |
Primary Endpoints |
CTR20244613 |
CTR20244613 | P1 |
Completed |
General Diabetes|Healthy Volunteers |
2025-06-09 |
2025-06-22 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06723691 |
HRS9531-107 | P1 |
Completed |
Type 2 Diabetes |
2025-06-09 |
88% |
2025-06-24 |
|
NCT06575933 |
MK-1084-009 | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2024-10-28 |
21% |
2024-11-09 |
Primary Endpoints|Treatments|Trial Status |
NCT06111521 |
LOXO-RAS-23007 | P1 |
Completed |
Breast Cancer |
2024-04-01 |
23% |
2024-07-23 |
Primary Endpoints |
NCT06118684 |
EP395-004 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-01-02 |
2024-02-29 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20230077 |
CTR20230077 | P1 |
Completed |
Influenza, Human |
2023-09-11 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT05541471 |
VX21-548-010 | P1 |
Completed |
Healthy Volunteers|Pain Unspecified |
2023-04-16 |
23% |
2024-03-21 |
Primary Endpoints|Treatments |
NCT07118215 |
CN012-0013 | P1 |
Recruiting |
Healthy Volunteers |
2026-04-05 |
88% |
2025-10-28 |
Primary Endpoints|Start Date |
NCT07215260 |
U1111-1317-7517 | P1 |
Completed |
Healthy Volunteers |
2025-12-07 |
88% |
2025-12-23 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT07065058 |
VCT220-I-04-01 | P1 |
Active, not recruiting |
Overweight|Obesity |
2025-10-31 |
88% |
2025-08-15 |
Primary Endpoints|Treatments|Trial Status |
NCT06921941 |
AT-01B-009 | P1 |
Completed |
Healthy Volunteers |
2025-07-02 |
50% |
2025-08-30 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06601517 |
HDM1002-106 | P1 |
Not yet recruiting |
Overweight |
2025-02-01 |
2% |
2024-09-24 |
Primary Endpoints |
NCT06416800 |
INCB54707-110 | P1 |
Completed |
Healthy Volunteers |
2025-01-15 |
50% |
2025-02-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06503679 |
J5C-MC-FOAF, DC-853104 | P1 |
Completed |
Healthy Volunteers |
2024-12-31 |
12% |
2025-01-25 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06597760 |
MK-0616-031 | P1 |
Completed |
Healthy Volunteers |
2024-11-01 |
50% |
2024-11-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
CTR20240762 |
CTR20240762 | P1 |
Completed |
Healthy Volunteers |
2024-05-20 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06293742 |
EC0007 | P1 |
Completed |
Type 2 Diabetes |
2024-04-15 |
12% |
2024-07-23 |
|
NCT06247748 |
dfbt-jy09-ow-2023-101 | P1 |
Completed |
Type 2 Diabetes|Overweight |
2024-04-15 |
2% |
2024-08-22 |
Primary Completion Date|Primary Endpoints |
CTR20230743 |
CTR20230743 | P1 |
Completed |
Healthy Volunteers |
2024-02-02 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06625827 |
MK-1026-012 | P1 |
Completed |
Healthy Volunteers |
2024-01-22 |
2024-10-04 |
Primary Endpoints|Treatments |
|
NCT06335134 |
SCW0502-1016 | P1 |
Completed |
Healthy Volunteers |
2024-01-08 |
12% |
2025-05-09 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05954624 |
ZSP1273-23-13 | P1 |
Completed |
Healthy Volunteers |
2023-11-20 |
12% |
2024-01-30 |
Primary Endpoints |
NCT05789342 |
GP681-202202 | P1 |
Completed |
Healthy Volunteers |
2023-09-11 |
23% |
2023-11-15 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT05815680 |
CIBI362D101 | P1 |
Completed |
Overweight |
2023-08-18 |
4% |
2025-08-27 |
Primary Endpoints|Treatments |